Is Apellis Pharmaceuticals Inc halal to invest in?

As of July 2026, Apellis Pharmaceuticals Inc APLS is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Apellis Pharmaceuticals Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Apellis Pharmaceuticals Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Apellis Pharmaceuticals Inc?

Muslim investors may consider investing in Apellis Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Apellis Pharmaceuticals Inc classified as HALAL?

Musaffa determines the Shariah status of Apellis Pharmaceuticals Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Apellis Pharmaceuticals Inc updated?

The Shariah compliance status of Apellis Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Apellis Pharmaceuticals Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Apellis Pharmaceuticals Inc?

You can check the latest Shariah compliance status of Apellis Pharmaceuticals Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

APLS Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Apellis Pharmaceuticals Inc is classified as halal.

HALAL

Report Source: 2026 1st Quarter Report

Apellis Pharmaceuticals Inc. Stock Analysis APLS

United States Health Care Mid Cap Report: Q1, 2026

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 733 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

Key Statistics of Apellis Pharmaceuticals Inc (APLS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$41.03$41.07

Today's Open

$41.05

Volume

68.61M

P/E Ratio (TTM)

234.62

52 Week Range

$16.10$41.14

Market Cap

5.25B

Avg. Volume

7.12M

Dividend Yield

Financial Metrics & Statements of Apellis Pharmaceuticals Inc (APLS)

Super Investors Invested in Apellis Pharmaceuticals Inc (APLS)

FAQ's for Apellis Pharmaceuticals Inc (APLS)

As of July 2026, Apellis Pharmaceuticals Inc APLS is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Apellis Pharmaceuticals Inc using these criteria to determine its compliance status.
Muslim investors may consider investing in Apellis Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Apellis Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Apellis Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Apellis Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.